临床与病理杂志2016，Vol.36Issue(10)：1531-1536,6.DOI:10.3978/j.issn.2095-6959.2016.10.013
地西他滨联合CAG方案治疗老年性及复发难治性急性髓细胞白血病的疗效分析
Clinical efficacy analysis of decitabine combined with CAG regiment on elderly and refractory or relapsed acute myeloid leukemia
摘要
Abstract
Objective:To investigate the therapeutic effectiveness and side effect of decitabine combined with CAG regimen on elderly and relapse or refractory patients with acute myeloid leukemia (AML). Methods:15 patients suffered from elderly or relapsed or refractory AML from January 2015 to December 2015 treated with decitabine combine with CAG regimen (decitabine 15 mg·m−2·d−1, d1~5, aclarubicin 10 mg/d, d3~6, Ara-C 10 mg/m2, q12 h, d3~9, G-CSF, 300 mg/d, d0~9), the therapeutic effectiveness and the side effect were observed. Results:Of 6 newly diagnosed elderly patients, 4 achieved complete remission (CR), 1 achieved partial remission (PR), the overall response rate (ORR) was 83.3%. Of 9 refractory or relapsed patients, 4 cases achieved CR, 2 cases achieved PR, and the ORR was 55.5%. The median overall survival time was 7 months (1~12 months). The median progression free survival time was 4 months (0~10 months). The hematologic toxicity rate was 100% and the severe bleeding rate was 10.5%, the incidence rate of infection was 73.3%. Neither liver and kidney injury, nor nausea and vomiting, at the degree of grade 3 or 4, was observed. Conclusion: Decitabine combined with CAG regiment can effectively treat elderly or refractory or relapsed AML, but hematologic toxicity and infections is severe, it is necessary to give appropriate monitoring and supportive treatment.关键词
急性髓细胞白血病/地西他滨/CAG方案/不良反应Key words
acute myeloid leukemia/decitabine/CAG regiment/adverse reaction引用本文复制引用
张前鹏,韩永胜..地西他滨联合CAG方案治疗老年性及复发难治性急性髓细胞白血病的疗效分析[J].临床与病理杂志,2016,36(10):1531-1536,6.基金项目
安徽省卫生厅临床医学应用技术(06B023)。@@@@This work was supported by Anhui Provincial Department of Health Clinical Application of Medical Technology (06B023), R. P. China （06B023）
